ArticlePloS one2022
Association between delayed initiation of treatment indications and survival in patients with cervical cancer: A systematic review and meta-analysis protocol.
Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Article
- Delayed treatment initiation is associated with worse survival in screening-detected patients with upper gastrointestinal cancer in rural China: a 10-year cohort study.Journal of global health · 2026Article
- Article
- Assessing predictors of brachytherapy utilization among cervical cancer patients in Nigeria: evidence from a tertiary cancer centre.BMC cancer · 2026Article
- Exploring the mediating roles of stigma and perceived social support between health literacy and health care decision-making barriers among patients with cervical cancer.Asia-Pacific journal of oncology nursing · 2025Article
- Cancer-specific thresholds of treatment initiation delay and assessment of their confounding variables: authors' reply.The Lancet regional health. Southeast Asia · 2025Article
- Surgical Staging in Locally Advanced Cervical Cancer: Precision, Risks, and the 'Helmet' Analogy.Cancers · 2025Article
- Article
- Access to timely cancer treatment initiation in India: extent, determinants and trends.The Lancet regional health. Southeast Asia · 2025Article
- Article
- Survival outcomes following treatment delays among patients with early-stage female cancers: a nationwide study.Journal of translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer is a growing public health problem globally. Despite the availability of management options, the progression of the disease as a function of waiting time may challenge the effort to attain a desired outcome. There is a conflicting report on the role of waiting time to initiate an appropriate treatment in improving patients' survival.
objectiveThis review aims to evaluate the association between delayed time to initiate any treatment indication with survival in patients with cervical cancer.
methodsAn internet-based literature search will be performed using text words, MESH terms and truncated words in databases, namely MEDLINE, Cochrane CENTRAL, EMBASE, Web of Science and Scopus. Grey literature searches in Google Scholar, Networked Digital Library of Theses and Dissertations (NDLTD) and Dissertations and Theses Global will be made. All articles published until 30th of December 2021 on human subjects will be searched without a language restriction. Studies which fulfil the inclusion criteria will be screened in full reading, selected, appraised and assessed for methodological quality by two independent reviewers. Data on participants, study methods, interventions, and outcomes will be abstracted. Included studies will be pooled for meta-analysis. Microsoft-Excel and R packages will be employed to carry out the statistical analysis. Heterogeneity will be assessed using Cochrane Q statistic, Tau2, and I2. Results will be reported as a function of 4-week delay in treatment initiation and the corresponding hazard ratio (HR) at 95% confidence interval. Statistical significance will be considered at P<0.05.
trial registrationPROSPERO registration number: CRD42022299689.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.